Physician profile
David Green
NPI 1902874704
$15,906.57
in general payments reported to CMS, 2019-2025
32 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,512 · 2020: $1,678 · 2021: $2,922 · 2022: $2,422 · 2023: $2,387 · 2024: $2,763 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,123 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,122.84 |
| Education | $251.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,208.45 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,001.99 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Actelion Pharmaceuticals US, INC. | $2,483.89 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $776.56 | 2020-2025 | Ofev, Jascayd, Spiriva Respimat |
| Insmed, INC. | $525.76 | 2019-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $521.25 | 2022-2025 | |
| Grifols USA, LLC | $454.58 | 2019-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $420.67 | 2019-2025 | Winrevair, Zerbaxa, Dificid |
| United Therapeutics Corporation | $354.13 | 2019-2025 | Tyvaso, Tyvaso |
| Shionogi INC | $286.60 | 2023-2025 | Fetroja |
| Amgen INC. | $280.03 | 2022-2025 | Tezspire |
| Alexion Pharmaceuticals, INC. | $274.03 | 2021-2024 | Ultomiris |
| Paratek Pharmaceuticals, INC. | $259.41 | 2020-2024 | Nuzyra |
| Genentech USA, INC. | $218.77 | 2019-2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $210.25 | 2021-2025 | Dupixent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $194.93 | 2020-2023 | Xarelto |
| La Jolla Pharmaceutical Company | $191.65 | 2019-2024 | Xacduro |
| Mylan Specialty L.P. | $188.73 | 2019-2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $176.61 | 2021-2024 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $172.69 | 2022-2023 | |
| Advanced Respiratory, INC | $166.64 | 2021 | |
| Gilead Sciences, INC. | $146.02 | 2019-2024 | Veklury |
| Baxter Healthcare | $113.17 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $78.78 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $67.40 | 2021 | |
| Novartis Pharmaceuticals Corporation | $41.65 | 2020 | |
| Boston Scientific Corporation | $27.48 | 2022 | |
| Ethicon INC. | $23.53 | 2022 | |
| Viatris Specialty LLC | $21.30 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $19.62 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.